CRL Charles River Laboratories International Inc.

Charles River Laboratories to Present at J.P. Morgan Healthcare Conference

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco, California on Tuesday, January 10th, at 1:30 p.m. PST (4:30 p.m. EST), followed by a question and answer session at 2:00 p.m. PST (5:00 p.m. EST). Management will present an overview of Charles River’s strategic focus, business developments, and recent trends.

A live webcast of the presentation and the subsequent question and answer session will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website approximately three hours after the presentation and will remain available for approximately two weeks.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

EN
09/01/2017

Underlying

Reports on Charles River Laboratories International Inc.

Charles River Laboratories Int'l, Inc.: Update to credit analysis

Charles River's credit profile reflects its strong and consistent free cash flow, offset by its sensitivity to R&D budgets of clients and research funding availability.

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Charles River Laboratories Int'l, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 23 December 2025 in which we reassessed the appropriateness of the r...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Back to Near-Term Bullish on SPX and QQQ We downgraded our near-term outlook on the S&P 500 (SPX) and Nasdaq 100 (QQQ) to neutral last week (11/19/25 Compass), after being bullish since our 4/22/25 Compass, while maintaining our intermediate-term bullish outlook (as of our 5/14/25 Compass). Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are right back to being near-term bullish as long as these support levels continue to hold. Just know that SPX could see...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

6550-6569 S&P 500 Support Holding For Now After 5.5-months, the S&P 500 (SPX) has now failed to break and stay below the its 20-day MA. However, 6569 has been our level that needs to break in order for us to have confidence that a pullback has begun; SPX made a low of 6551 on Friday (less than 20 points or 0.3% from our 6569 level), meaning it was not a decisive breakdown (in time or price). As a result, our near-term bullish outlook since our 4/22/25 Compass remains intact, and it will stay t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch